Skip to content

Revogene GBS LB 410200

by Meridian Bioscience Inc.

Revogene GBS LB 410200 is a medical device (FDA Class I) made by Meridian Bioscience Inc., cleared under FDA 510(k) K170557 on 25 May 2017 and listed in FDA GUDID since 15 Jul 2020 (UDI-DI 00840733102363), active as of 8 Nov 2026.

Active United States. Also listed in GUDID (US).

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 8 Nov 2026

Documents

510(k) K170557

FDA submission, from GUDID

Trust

Unverified

Source GUDID, synced 8 Nov 2026.

Regulatory status

as of registry sync 8 Nov 2026

RegionAuthorizationNumberDateStatus
United StatesGUDID listing Number00840733102363 UDI-DI Date15 Jul 2020ListedStatusListed GUDID: in commercial distribution
United StatesFDA 510(k)SESE from GUDID Substantially Equivalent · Traditional NumberK170557 Date25 May 2017DecidedStatusActive

Official records

From the FDA record

Device description
The Revogene GBS LB assay performed on the Revogene Instrument is a qualitative in vitro diagnostic test designed to detect Group B Streptococcus (GBS) DNA from 18-24 hour LIM Broth enrichments of vaginal/rectal specimen swabs obtained from pregnant women. The Revogene GBS LB assay utilizes Automated sample processing and real-time polymerase chain reaction (PCR) to detect a cfb gene sequence specific to the Streptococcus agalactiae genome. The Revogene GBS LB assay is indicated for the identification of antepartum GBS colonization and does not provide susceptibility results. it is not intended to diagnose or monitor treatment of GBS infection. Culture isolates are needed for performing susceptibility testing as recommended for penicillin-allergic women.
MRI safety
Labeling does not contain MRI Safety Information
Natural rubber latex
No latex statement on the label
Sterility
Supplied non-sterile

From the GUDID record (AccessGUDID), as read on 8 Nov 2026, as the labeller entered it.

Across registries

2 registries list this device

  • FDA 510(k) K170557 decided 25 May 2017 Active
  • FDA GUDID UDI-DI 00840733102363 listed 15 Jul 2020 Listed

Timeline

2 dated events

  1. Cleared FDA 510(k) K170557
  2. Listed FDA GUDID 00840733102363

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

GUDID

Trade name
Revogene GBS LB
Generic name
Beta-haemolytic Group B Streptococcus nucleic acid IVD, kit, nucleic acid technique (NAT)
Model / Ref / Catalog
410200
Primary DI / UDI-DI
00840733102363
510(k) Number
FDA product code
NJR, OOI
GMDN term
Beta-haemolytic Group B Streptococcus nucleic acid IVD, kit, nucleic acid technique (NAT)
Device class
Class I
Regulation number
866.3740, 862.2570
GUDID distribution status
In Commercial Distribution

Similar devices in this category

Other devices filed under Beta-haemolytic Group B Streptococcus nucleic acid IVD, kit, nucleic acid technique (NAT).

Other devices from Meridian Bioscience Inc.

See all devices from Meridian Bioscience Inc. →

Properties

  • Single use
  • Prescription use
  • Convenience kit
  • Lot / batch number
  • Expiration date
Other properties (10, all answered No)